Walker named new COO of City of Hope

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Jeff Walker, formerly a chief operating officer at Ohio State University, has been named COO of City of Hope.

Walker has more than two decades of experience in cancer center leadership and transformation. He joined City of Hope earlier this year as senior vice president in transformation development and has been leading the institution’s efforts around operational design and planning for new strategic initiatives and ventures.

As COO, Walker will lead patient care operations for the Duarte, California, campus and all community practice locations as well as all research operations. He will oversee the management of the enterprise-wide physical plant, including an estimated $1.1 billion in new construction projects.

Prior to coming to City of Hope, Walker served as the chief operating officer for The Ohio State University Comprehensive Cancer Center and the James Cancer Hospital, overseeing and integrating the administrative and operational structure to support the program’s research and clinical missions. During his tenure, the new James Cancer Hospital was built and opened, becoming the third largest cancer hospital in the country.

Walker has also served as executive vice president for the Roswell Park Cancer Research Institute in New York and, prior to his roles at Ohio State and Roswell Park, he held administrative leadership positions at the University of Pittsburgh Cancer Institute during his 14 years at UPCI.

Walker serves as vice-chair of the Alliance of Dedicated Cancer Center executive committee, treasurer of the Association of American Cancer Institutes, and is a member of the executive and finance committees of the National Comprehensive Cancer Network and the Cancer Center Administrators Forum.

YOU MAY BE INTERESTED IN

More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.

Login